GERN News & Events

Reports Q1 revenue $51.84M, consensus $50.59M. "We are encouraged by RYTELO demand and net revenue growth in the first quarter. Our refocused commercial strategy, energized team, and commitment to execute with excellence position us well to continue building on these results," said Harout Semerjian, President and Chief Executive Officer of Geron. "We also made progress on our potential European lower-risk MDS commercial strategy for RYTELO, with the goal of maximizing its value while preserving pricing integrity in the U.S. We plan to provide an update on our European commercial plans by the end of the year. Our 2026 priorities remain focused on growing RYTELO net revenue in the U.S., pursuing pathways to bring RYTELO to patients outside of the U.S., advancing our Phase 3 IMpactMF trial, remaining financially disciplined, and evaluating opportunistic innovation, as we work towards building a leading hematology company."

Geron (GERN) announced the appointment of Timothy Williams as executive VP, chief legal officer and corporate secretary. Tim Williams served as senior VP, general counsel and Secretary at Vanda Pharmaceuticals (VNDA) from 2018 until March.

Geron files automatic mixed securities shelf

For fiscal year 2026, the Company expects Rytelo net product revenue to be in the range of $220 million to $240 million. Geron also expects total operating expenses to be between $230 million and $240 million. Total operating expenses include non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, and depreciation and amortization. Based on current operating plans and assumptions, the Company believes that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of Rytelo, will be sufficient to fund projected operating requirements for the foreseeable future.